It is very uncertain whether cognitive behavioural therapy and other therapies changes arrested for any crime at 6 months compared with prison therapeutic community (very low certainty).
It is very uncertain whether cognitive behavioural therapy and other therapies changes criminal activity at 6 months compared with prison therapeutic community (very low certainty).
It is very uncertain whether cognitive behavioural therapy and other therapies changes drug‐related crime at 6 months compared with prison therapeutic community (very low certainty).
It is very uncertain whether cognitive behavioural therapy and other therapies changes arrested (not parole violation) at 6 months compared with prison therapeutic community (very low certainty).
It is very uncertain whether cognitive behavioural therapy and other therapies changes self‐reported drug use at 6 months compared with prison therapeutic community (very low certainty).
Cognitive behavioural therapy and other therapies showed no clear difference in reincarcerated at 12 months after parole compared with prison therapeutic community (low certainty).
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: baclofen versus clonidine compared with other pharmacological detoxification treatment (very low certainty).
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: clonidine versus clonidine plus amantadine,… compared with other pharmacological detoxification treatment (very low certainty).
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: clonidine versus buprenorphine, inpatient… compared with other pharmacological detoxification treatment (very low certainty).
Pharmacological detoxification treatment showed no clear difference in completion of treatment: methadone versus methadone plus gabapentin compared with other pharmacological detoxification treatment (low certainty).
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants abstinent at end of treatment compared with placebo (moderate certainty).
Mixed action antidepressant showed no clear difference in participants experiencing adverse effects compared with placebo (low certainty).
Mixed action antidepressant showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
Mixed action antidepressant showed no clear difference in completion of scheduled treatment compared with placebo (low certainty).
It is very uncertain whether anticonvulsants and mood stabilisers changes participants abstinent at end of treatment compared with placebo (very low certainty).
It is very uncertain whether anticonvulsants and mood stabilisers changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
Anticonvulsants and mood stabilisers may leads to lower completion of scheduled treatment compared with placebo (low certainty).
Buspirone showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).
Buspirone showed no clear difference in participants experiencing adverse effects compared with placebo (low certainty).